FRX vs. MDNA, ONC, SVA, KSI, VHI, DR, OGI, QIPT, CPH, and ACB
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Medicenna Therapeutics (MDNA), Oncolytics Biotech (ONC), Sernova (SVA), kneat.com (KSI), Vitalhub (VHI), Medical Facilities (DR), Organigram (OGI), Quipt Home Medical (QIPT), Cipher Pharmaceuticals (CPH), and Aurora Cannabis (ACB). These companies are all part of the "medical" sector.
Fennec Pharmaceuticals (TSE:FRX) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, community ranking, earnings, dividends and profitability.
Fennec Pharmaceuticals received 15 more outperform votes than Medicenna Therapeutics when rated by MarketBeat users. Likewise, 69.59% of users gave Fennec Pharmaceuticals an outperform vote while only 68.22% of users gave Medicenna Therapeutics an outperform vote.
Fennec Pharmaceuticals has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Medicenna Therapeutics has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.
55.3% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.9% of Medicenna Therapeutics shares are owned by institutional investors. 14.6% of Fennec Pharmaceuticals shares are owned by insiders. Comparatively, 23.7% of Medicenna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Medicenna Therapeutics has lower revenue, but higher earnings than Fennec Pharmaceuticals. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.
Medicenna Therapeutics has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -75.50%. Medicenna Therapeutics' return on equity of -59.47% beat Fennec Pharmaceuticals' return on equity.
In the previous week, Fennec Pharmaceuticals had 5 more articles in the media than Medicenna Therapeutics. MarketBeat recorded 6 mentions for Fennec Pharmaceuticals and 1 mentions for Medicenna Therapeutics. Fennec Pharmaceuticals' average media sentiment score of 0.77 beat Medicenna Therapeutics' score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media.
Summary
Fennec Pharmaceuticals and Medicenna Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
